deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00468715

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study

Sponsor: AstraZeneca

Conditions Breast Cancer
Interventions bicalutamide diagnostic laboratory biomarker analysis immunohistochemistry staining method
Updated 15 times since 2017 Last updated: Jul 8, 2022 Started: Mar 23, 2007 Primary completion: Jun 24, 2021 Completion: Jun 24, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 15 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 10 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Completed PHASE2

  2. Sep 2021 — Sep 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. May 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  8. May 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations